BR112017012136A2 - Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr - Google Patents

Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr

Info

Publication number
BR112017012136A2
BR112017012136A2 BR112017012136-0A BR112017012136A BR112017012136A2 BR 112017012136 A2 BR112017012136 A2 BR 112017012136A2 BR 112017012136 A BR112017012136 A BR 112017012136A BR 112017012136 A2 BR112017012136 A2 BR 112017012136A2
Authority
BR
Brazil
Prior art keywords
oxo
combination
hydro
anticancer activity
egfr inhibitor
Prior art date
Application number
BR112017012136-0A
Other languages
English (en)
Inventor
Bladt Friedhelm
Friese-Hamim Manja
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52133768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017012136(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112017012136A2 publication Critical patent/BR112017012136A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a uma composição farma-cêutica de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetóxi)-pirimidin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila ou um sal farmaceutica-mente aceitável e/ou solvato da mesma em combinação com n-[3-[[2-[4-(4-acetilpiperazin-1-il)-2-metóxi-anilino]-5-(trifluorometil)pirimidin-4-il]amino]fenil]prop-2-enamida.
BR112017012136-0A 2014-12-12 2015-11-12 Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr BR112017012136A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14004200.3 2014-12-12
EP14004200 2014-12-12
PCT/EP2015/002265 WO2016091346A1 (en) 2014-12-12 2015-11-12 Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor

Publications (1)

Publication Number Publication Date
BR112017012136A2 true BR112017012136A2 (pt) 2018-01-02

Family

ID=52133768

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012136-0A BR112017012136A2 (pt) 2014-12-12 2015-11-12 Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr

Country Status (17)

Country Link
US (2) US10532052B2 (pt)
EP (1) EP3229806A1 (pt)
JP (1) JP2017537939A (pt)
KR (1) KR20170090499A (pt)
CN (1) CN106999493A (pt)
AU (1) AU2015360005A1 (pt)
BR (1) BR112017012136A2 (pt)
CA (1) CA2970391A1 (pt)
CL (1) CL2017001478A1 (pt)
IL (1) IL252752A0 (pt)
MX (1) MX2017007372A (pt)
PH (1) PH12017500718A1 (pt)
RU (1) RU2017124612A (pt)
SG (1) SG11201704767YA (pt)
UA (1) UA120108C2 (pt)
WO (1) WO2016091346A1 (pt)
ZA (1) ZA201704654B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI739206B (zh) 2014-12-12 2021-09-11 日商日本煙草產業股份有限公司 二氫嘧啶-2-酮化合物及其醫藥用途
KR20200126973A (ko) 2018-02-28 2020-11-09 니뽄 다바코 산교 가부시키가이샤 4-메틸디히드로피리미디논 화합물 및 그의 의약 용도
US11455294B2 (en) * 2019-10-18 2022-09-27 Sap Se Information lifecycle management notification framework

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US20090155247A1 (en) 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
AU2009300328A1 (en) * 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
CA2749012C (en) 2009-01-08 2017-01-31 Merck Patent Gmbh Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
MY181898A (en) 2010-11-01 2021-01-12 Celgene Car Llc Heterocyclic compounds and uses thereof
MY169233A (en) 2012-03-15 2019-03-19 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
MX2014010982A (es) 2012-03-19 2014-10-13 Merck Patent Gmbh Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancerosa con otros compuestos antitumorales.
RU2660354C2 (ru) * 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
CN104703655A (zh) 2012-10-11 2015-06-10 默克专利股份公司 具有抗-癌活性的6-氧代-1,6-二氢-哒嗪衍生物与mek抑制剂的组合
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته

Also Published As

Publication number Publication date
WO2016091346A1 (en) 2016-06-16
PH12017500718A1 (en) 2017-10-09
RU2017124612A (ru) 2019-01-14
US10532052B2 (en) 2020-01-14
KR20170090499A (ko) 2017-08-07
CL2017001478A1 (es) 2018-01-05
SG11201704767YA (en) 2017-07-28
JP2017537939A (ja) 2017-12-21
RU2017124612A3 (pt) 2019-06-05
UA120108C2 (uk) 2019-10-10
US20190388423A1 (en) 2019-12-26
CA2970391A1 (en) 2016-06-16
ZA201704654B (en) 2019-08-28
AU2015360005A1 (en) 2017-07-27
IL252752A0 (en) 2017-08-31
US20170319581A1 (en) 2017-11-09
MX2017007372A (es) 2017-11-06
CN106999493A (zh) 2017-08-01
EP3229806A1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
CY1124998T1 (el) Ετεροκυκλικες ενωσεις και χρήσεις αυτων
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
MD3464265T2 (ro) Polimorfi de N-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoximetil)-1-({4-[2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carboxamidă ca inhibitori de kalicreină
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
DK2373640T3 (da) Hidtil ukendte polymorfe former af 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitril-hydrochloridsalt og fremgangsmåder til fremstilling deraf
EA202091120A2 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
BR112019004356A2 (pt) composições de comprimido
BR112017012136A2 (pt) Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr
BR112015010121A2 (pt) inibidores de quinase de tirosina de bruton
PH12017500719A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
ECSP099673A (es) Formas sólidas de un inhibidor de cinasa raf
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
BR112015030171A2 (pt) composto, composição farmacêutica, método para prevenir ou tratar uma doença ou seus sintomas, uma afecção ou um distúrbio mediado parcial ou completamente por receptores nicotínicos de acetilcolina, uso de 4-(5-(4- clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol-3-il) benzenossulfonamida
EA202091279A1 (ru) Полиморфы и твердые формы пиримидиниламино-пиразолового соединения и способы их получения
PE20170926A1 (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson
BR112015007870A2 (pt) combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com um inibidor de mek
PH12016500948A1 (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
MA35636B1 (fr) Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide
BR112015008279A2 (pt) derivado de 6-oxo-1,6-di-hidro-piridazina para uso no tratamento de carcinoma hepatocelular (hcc)
BR112017012547A2 (pt) Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas
BR112022000266A2 (pt) Preparação farmacêutica
DK3585776T3 (da) 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitril-forbindelser som ikke, tbk1 og/eller sik2 kinaseinhibitorer
EA201591300A1 (ru) Формы меглуминовой соли 2-((1r,4r)-4-(4-(5-(бензоксазол-2-иламино)пиридин-2-ил)фенил)циклогексил)уксусной кислоты и их применение в качестве ингибиторов dgat1
PH12016500964A1 (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
BR112021024194A2 (pt) Formulação de liberação modificada de um composto de pirimidinilamino-pirazol e métodos de tratamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements